title: Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat.
abstract: Gender differences in the incidence of cardiovascular disease have been related to plasma estrogen levels; however, the role of vascular estrogen receptor (ER) subtypes in these sex differences is less clear. We tested whether the gender differences in vascular smooth muscle (VSM) function reflect differential expression/activity of ERalpha, ERbeta and the newly-identified GPR30. Single aortic VSM cells (VSMCs) were freshly isolated from male and female Sprague-Dawley rats, and their contraction to phenylephrine (PHE, 10(-5) M), AngII (10(-7) M) and membrane-depolarization by KCl (51 mM) was measured in the absence or presence of 10(-6) M 17beta-estradiol (E2, stimulant of most ERs), PPT (ERalpha agonist), DPN (ERbeta agonist), and ICI 182,780 (an ERalpha/ERbeta antagonist with GPR30 agonistic properties). The cells were fixed and fluorescently labeled with ERalpha, ERbeta or GPR30 antibody, and the subcellular distribution of ERs was examined using digital imaging microscopy. The mRNA expression and protein amount of aortic ER subtypes was examined using RT-PCR and Western blots. PHE, AngII, and KCl caused less contraction in VSMCs of females than males. Pretreatment of VSMCs with E2 reduced PHE-, AngII- and KCl-induced contraction in both males and females. PPT caused similar inhibition of PHE-, AngII- and KCl-induced contraction as E2, suggesting a role of ERalpha. DPN mainly inhibited PHE and KCl contraction, suggesting an interaction between ERbeta and Ca(2+) channels. ICI 182,780 did not reduce aortic VSMC contraction, suggesting little role for GPR30. RT-PCR and Western blots revealed greater expression of ERalpha and ERbeta in VSMCs of females than males, but similar amounts of GPR30. The total immunofluorescence signal for ERalpha and ERbeta was greater in VSMCs of females than males, and was largely localized in the nucleus. GPR30 fluorescence was similar in VSMCs of males and females, and was mainly in the cytosol. In PPT treated cells, nuclear ERalpha signal was enhanced. DPN did not affect the distribution of ERbeta, and ICI 182,780 did not significantly increase GPR30 in the cell surface. Thus, ER subtypes demonstrate similar responsiveness to specific agonists in VSMCs of male and female rats. The reduced contraction in VSMCs of females could be due to gender-related increase in the expression of ERalpha and ERbeta.
authors.affiliation: Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston.
authors.forename: Yukui
authors.initials: Y
authors.lastname: Ma
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Qiao
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Falone
authors.forename: Ossama M
authors.initials: OM
authors.lastname: Reslan
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Sheppard
authors.forename: Raouf A
authors.initials: RA
authors.lastname: Khalil
mesh_terms: D000818:Animals; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005260:Female; D000077267:Fulvestrant; D036145:Ginsenosides / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000502:physiology*; D009243:NAD / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism; D012502:Sapogenins / Q000494:pharmacology; D012737:Sex Factors
chemical_list: D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D036145:Ginsenosides; C520305:Gper1 protein, rat; D043562:Receptors, G-Protein-Coupled; D012502:Sapogenins; C507965:ginsenoside 20S-protopanaxatriol; D009243:NAD; D000077267:Fulvestrant; D004958:Estradiol; D011189:Potassium Chloride
references.citation: Curr Med Chem Cardiovasc Hematol Agents. 2005 Oct;3(4):305-22
references.pmid: 16250862
references.citation: Artery. 1983;12(1):1-23
references.pmid: 6431945
references.citation: Am J Cardiol. 2002 Jul 3;90(1A):3F-6F
references.pmid: 12106632
references.citation: Expert Rev Cardiovasc Ther. 2007 Jul;5(4):777-89
references.pmid: 17605655
references.citation: FEBS Lett. 2008 Mar 5;582(5):635-42
references.pmid: 18242172
references.citation: Mol Cell Endocrinol. 2003 Aug 29;206(1-2):13-22
references.pmid: 12943986
references.citation: Am J Physiol. 1994 Apr;266(4 Pt 1):C975-80
references.pmid: 8178970
references.citation: J Pharmacol Exp Ther. 2005 Jun;313(3):1203-8
references.pmid: 15722404
references.citation: Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R233-49
references.pmid: 14707008
references.citation: Mol Pharmacol. 2008 Dec;74(6):1533-43
references.pmid: 18768737
references.citation: Am J Physiol. 1992 Sep;263(3 Pt 1):C714-9
references.pmid: 1415520
references.citation: Am J Physiol Cell Physiol. 2003 Dec;285(6):C1437-44
references.pmid: 12890645
references.citation: Mol Endocrinol. 2000 Oct;14(10):1649-60
references.pmid: 11043579
references.citation: Curr Med Chem. 2009;16(15):1863-87
references.pmid: 19442151
references.citation: J Physiol. 2006 Dec 15;577(Pt 3):945-55
references.pmid: 17038424
references.citation: Am J Physiol Cell Physiol. 2001 Jan;280(1):C34-45
references.pmid: 11121374
references.citation: Arteriosclerosis. 1985 Nov-Dec;5(6):668-77
references.pmid: 4074199
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1486-93
references.pmid: 18832085
references.citation: Atherosclerosis. 2008 Jan;196(1):49-58
references.pmid: 17367797
references.citation: Hypertension. 2007 Jun;49(6):1358-63
references.pmid: 17452498
references.citation: Circulation. 1995 Jul 1;92(1):5-8
references.pmid: 7788916
references.citation: J Pharmacol Exp Ther. 1988 Jan;244(1):19-22
references.pmid: 3121846
references.citation: Am J Physiol Cell Physiol. 2000 Apr;278(4):C834-44
references.pmid: 10751331
references.citation: J Pharmacol Exp Ther. 1988 Feb;244(2):537-42
references.pmid: 3346836
references.citation: J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S99-101
references.pmid: 11078348
references.citation: Gynecol Endocrinol. 2009 Feb;25(2):82-95
references.pmid: 19253103
references.citation: Hypertension. 2004 Dec;44(6):789-95
references.pmid: 15477384
references.citation: Am J Cardiol. 1994 May 15;73(13):951-2
references.pmid: 8184850
references.citation: Eur J Pharmacol. 2002 Jun 12;445(3):247-56
references.pmid: 12079690
references.citation: Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1295-306
references.pmid: 12531733
references.citation: Hypertension. 1999 Oct;34(4 Pt 2):931-6
references.pmid: 10523387
references.citation: Clin Exp Pharmacol Physiol. 1996 Mar;23(3):256-9
references.pmid: 8934618
references.citation: Crit Rev Eukaryot Gene Expr. 1992;2(1):19-63
references.pmid: 1543897
references.citation: Circ Res. 2005 Oct 14;97(8):829-36
references.pmid: 16151024
references.citation: Peptides. 2008 Aug;29(8):1338-46
references.pmid: 18486991
references.citation: Circ Res. 2000 Nov 24;87(11):E44-52
references.pmid: 11090554
references.citation: Circ Res. 1991 Dec;69(6):1626-31
references.pmid: 1954682
references.citation: Am J Physiol. 1997 Apr;272(4 Pt 2):H1819-25
references.pmid: 9139968
references.citation: Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1034-40
references.pmid: 10195933
references.citation: J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1):4-10
references.pmid: 11881054
references.citation: Circ Res. 2002 May 31;90(10):1087-92
references.pmid: 12039798
references.citation: J Vasc Surg. 2010 Apr;51(4):972-81
references.pmid: 20347696
references.citation: Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86
references.pmid: 18991792
references.citation: Circ Res. 1972 Mar;30(3):341-9
references.pmid: 5060434
references.citation: Am J Physiol. 1997 Nov;273(5):H2325-32
references.pmid: 9374769
references.citation: Gynecol Endocrinol. 2006 Jan;22(1):44-7
references.pmid: 16522533
references.citation: Science. 2002 Jan 18;295(5554):505-8
references.pmid: 11799247
references.citation: J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):350-3
references.pmid: 18406603
references.citation: FEBS Lett. 2009 Nov 3;583(21):3448-54
references.pmid: 19804776
references.citation: Br J Pharmacol. 1991 Dec;104(4):1033-7
references.pmid: 1810590
references.citation: Endocrinology. 1999 Feb;140(2):800-4
references.pmid: 9927308
references.citation: J Am Coll Cardiol. 1992 Aug;20(2):458-9
references.pmid: 1634686
references.citation: Mol Endocrinol. 2008 Nov;22(11):2544-56
references.pmid: 18787042
references.citation: Endocrinology. 2007 Jul;148(7):3236-45
references.pmid: 17379646
references.citation: J Med Chem. 2000 Dec 28;43(26):4934-47
references.pmid: 11150164
references.citation: J Clin Invest. 1997 May 15;99(10):2429-37
references.pmid: 9153286
references.citation: Eur J Pharmacol. 1995 Dec 29;294(2-3):625-35
references.pmid: 8750727
references.citation: Circ Res. 1984 Aug;55(2):227-37
references.pmid: 6744532
references.citation: J Physiol. 1992 Sep;455:585-99
references.pmid: 1484363
references.citation: J Pharmacol Sci. 2007 Sep;105(1):74-81
references.pmid: 17895590
references.citation: Am J Physiol. 1998 Jul;275(1):H292-300
references.pmid: 9688926
references.citation: JAMA. 1991 Apr 10;265(14):1861-7
references.pmid: 2005736
references.citation: Science. 2005 Mar 11;307(5715):1625-30
references.pmid: 15705806
references.citation: Br J Pharmacol. 2003 Aug;139(7):1249-53
references.pmid: 12890703
references.citation: Science. 2005 Jun 10;308(5728):1583-7
references.pmid: 15947175
references.citation: Cell Signal. 2004 Mar;16(3):301-11
references.pmid: 14687660